Baxter/Allegiance/Premier purchasing deal to generate $1 bil. in annual sales.
This article was originally published in The Gray Sheet
BAXTER, PREMIER DISCUSSING CARDIOVASCULAR PRODUCTS SUPPLY CONTRACT, building on a seven-year agreement covering medical and surgical devices signed Nov. 14 by Baxter Healthcare, Baxter spin-off Allegiance Healthcare and Premier, a hospital and health system alliance. The broad supply agreement, scheduled to take effect Feb. 1, 1997, is estimated to be worth approximately $1 bil. in annual sales. Baxter's cardiovascular revenues accounted for approximately 14% ($730 mil.) of total 1995 sales of $5.048 bil.
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.